Coverage / CTXR / Trade Card

CTXR

Citius Pharmaceuticals Inc

OPPORTUNISTIC BUY 2026-08-01 Updated today USD 0.57 Healthcare - BiotechnologyAWAIT ENTRY
59

Position levels

Currenttoday
USD 0.57
Buy <=wait / entry
USD 0.47
Trim >=take some off
USD 0.80
Thesis breakA negative FDA action on LYMPHIR or Mino-Lok, a clean quarterly LYMPHIR revenue ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Strong Buy analyst ratings from 2 firms with price targets of $4-$5 per share
  • Projected revenues of $156M in 2031 from LYMPHIR approval and commercialization
  • Late-stage pipeline including Mino-Lok and Halo-Lido in oncology and anti-infectives
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.